-
-
Sequence
- GIGKFLKKAKKFGKAFVKILKK
-
Sequence Name
- MSI-78(Pexiganan)
-
Description
- a broad-spectrum synthetic analogue of the African frog peptide magainin
-
-
Medical use
- treatment of diabetic foot ulcers
-
Stage of Development
- Phase III(denied approval for use in 1999
-
- Pexiganan resulted in either clearance of the pathogen or significant improvement in over 90% of patients, with a good toxicity profile. Despite these encouraging results, Pexiganan was denied approval for use in 1999 on the basis of insufficient evidence of efficacy.
-
Company
- Genaera (Plymouth, PA)
-
Target Organism
-
- Gram-positive bacteria:
Staphylococcus aureus ATCC 29213 (MIC=8-16 μg/ml), Staphylococcus aureus ATCC 33591 (methicillin resistant) (MIC=16-32 μg/ml), Staphylococcus epidermidis ATCC 12228 (MIC=2-4 μg/ml), Enterococcus faecium ATCC 51559 (vancomycin resistant) (MIC=8 μg/ml), Enterococcus faecalis ATCC 29212 (MIC=64 μg/ml), Group A Streptococcus ATCC 49399 (MIC=4 μg/ml), Streptococcus pneumoniae ATCC 49619 (MIC=32 μg/ml), Streptococcus bovis ATCC 49133 (MIC=4 μg/ml), Bacillus cereus ATCC 11778 (MIC=8 μg/ml), Micrococcus luteus ATCC 4698 (MIC=2 μg/ml), Corynebacterium group A ATCC 49676 (MIC=2-4 μg/ml); - Gram-negative bacteria:
Escherichia coli ATCC 25922 (MIC=8-16 μg/ml), Enterobacter cloacae ATCC 35030 (MIC=8 μg/ml), Proteus mirabilis ATCC 29245 (MIC>256 μg/ml), Serratia marcescens ATCC 8100 (MIC>256 μg/ml), Helicobacter pylori ATCC 43504 (MIC=2 μg/ml), Haemophilus influenzae ATCC 49247 (MIC=8 μg/ml), Pseudomonas aeruginosa ATCC 27853 (MIC=8-16 μg/ml), Bacteroides fragilis ATCC 90028 (MIC=2-4 μg/ml), eroides thetaiotaomicron ATCC 29741 (MIC=2-4 μg/ml), Clostridium difficile ATCC 43255 (MIC=4 μg/ml), Propionibacterium acnes ATCC 29399 (MIC=8 μg/ml), Veillonella parvula ATCC 10790 (MIC=8 μg/ml).
-
Reference
-
- In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob. Agents Chemother(1999).(PMID: 10103181)
- Pexiganan acetate. Drugs (1998)